Ameet Dhar
Overview
Explore the profile of Ameet Dhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vithayathil M, Qurashi M, Vicente P, Alsafi A, Naik M, Graham A, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123437
Background: Biannual ultrasound (US) is recommended for hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis. However, US has limited sensitivity for early-stage HCC, particularly in overweight cohorts, where hepatic visualisation...
2.
Hong A, Sarwar N, Goldin R, Dhar A, Possamai L
Cureus
. 2022 Aug;
14(7):e26596.
PMID: 35936135
Anti-programmed death receptor-1 (anti-PD-1) monoclonal antibodies (mAbs) are used to treat an increasing range of cancers. However, the distinct toxicity profile of immune-related adverse events (irAEs) is a frequent drawback...
3.
Forlano R, Mullish B, Dhar A, Goldin R, Thursz M, Manousou P
World J Hepatol
. 2022 Jan;
13(12):2104-2112.
PMID: 35070011
Background: Metabolic-associated fatty liver disease (MAFLD) is the commonest cause of abnormal liver function tests (LFTs). Current upper normal of limit (UNL) of LFTs was derived from a "healthy" population,...
4.
Nathwani R, Kockerling D, Mullish B, Cole A, Lemoine M, Antoniades C, et al.
Frontline Gastroenterol
. 2021 Dec;
13(1):86-88.
PMID: 34970431
No abstract available.
5.
Gudd C, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, et al.
J Hepatol
. 2021 Feb;
75(1):177-189.
PMID: 33631227
Background & Aims: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid subsets. Methods:...
6.
Forlano R, Mullish B, Mukherjee S, Nathwani R, Harlow C, Crook P, et al.
PLoS One
. 2020 Oct;
15(10):e0240400.
PMID: 33031439
Background & Aims: Although metabolic risk factors are associated with more severe COVID-19, there is little evidence on outcomes in patients with non-alcoholic fatty liver disease (NAFLD). We here describe...
7.
Kim J, Majid A, Judge R, Crook P, Nathwani R, Selvapatt N, et al.
Lancet Gastroenterol Hepatol
. 2020 Aug;
5(10):886-887.
PMID: 32763197
No abstract available.
8.
Bernsmeier C, Cavazza A, Fatourou E, Theocharidou E, Akintimehin A, Baumgartner B, et al.
Aliment Pharmacol Ther
. 2020 Jul;
52(5):855-865.
PMID: 32683724
Background: In patients with cirrhosis, progression to acute decompensation (AD) and acute-on-chronic liver failure (ACLF) has been associated with poor prognosis. Differential leucocyte ratios might predict mortality in systemic inflammatory...
9.
Nathwani R, Mukherjee S, Forlano R, Mullish B, Vergis N, Selvapatt N, et al.
Aliment Pharmacol Ther
. 2020 Jul;
52(3):572-574.
PMID: 32656833
No abstract available.
10.
Forlano R, Mullish B, Nathwani R, Dhar A, Thursz M, Manousou P
Curr Vasc Pharmacol
. 2020 Mar;
19(3):269-279.
PMID: 32188385
Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD),...